Shuaiying Cui PhD
Boston University School of Medicine, United States · United States
Editorial leadership for Journal of Hematology and Oncology Research ISSN 2372-6601
Research interests
- Hematologic Disorders
- Sickle Cell Disease
- Beta-Thalassemia
- Acute Myeloid Leukemia
- Blood Cancer
Biography
Dr. Shuaiying Cui is affiliated with Boston University School of Medicine, United States, where research has focused on the development of novel agents that can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells and progenitors through epigenetic chromatin modifications by nucleosome remodeling, histone deacetylation, and demethylation. Such agents can be applied to the treatment of patients with hematologic disorders such as sickle cell disease and beta-thalassemia, as well as acute myeloid leukemia, which arise from congenital defects in the genome. Dr. Cui's most-cited publication, "The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice" (2015), has been cited 84 times and exemplifies this translational approach. The findings from these preclinical studies could also help to establish therapeutic indications in other hematological malignancies.
Selected publications
- The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice 2015 cited 84×
- Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic β-type globin genes 2015 cited 23×
- Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays 2017 cited 19×
- Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis 2019 cited 16×
- Pharmacologic induction of PGC‐1α stimulates fetal haemoglobin gene expression 2022 cited 12×
- PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease 2024 cited 10×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JHOR for your work?
This journal is guided by Shuaiying Cui (Boston University School of Medicine, United States) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.